Iodoquinol: Difference between revisions
Gerald Chi (talk | contribs) m (→Package Insert) |
Gerald Chi (talk | contribs) m (→Overview) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The [[quinoline]] derivative diiodohydroxyquinoline ([[International Nonproprietary Name|INN]]) or iodoquinol ([[United States Adopted Name|USAN]]) can be used in the treatment of ''[[amebiasis]]'', ''[[balantidiasis]]'', and ''[[Dientamoeba fragilis]]''.<ref name="pmid2493578">{{cite journal |author=Ghaskadbi S, Vaidya VG |title=In vivo antimutagenic effect of ascorbic acid against mutagenicity of the common antiamebic drug diiodohydroxyquinoline |journal=Mutat. Res. |volume=222 |issue=3 |pages=219–22 |year=1989 |month=March |pmid=2493578 |doi= 10.1016/0165-1218(89)90137-7|url=}}</ref> It is poorly absorbed from the [[gastrointestinal tract]] and is used as a luminal agent to eradicate both [[cyst]]s and [[trophozoite]]s infestating the lumen of the gastrointestinal tract. | The [[quinoline]] derivative diiodohydroxyquinoline ([[International Nonproprietary Name|INN]]) or iodoquinol ([[United States Adopted Name|USAN]]) can be used in the treatment of ''[[amebiasis]]'', ''[[balantidiasis]]'', and ''[[Dientamoeba fragilis]]''.<ref name="pmid2493578">{{cite journal |author=Ghaskadbi S, Vaidya VG |title=In vivo antimutagenic effect of ascorbic acid against mutagenicity of the common antiamebic drug diiodohydroxyquinoline |journal=Mutat. Res. |volume=222 |issue=3 |pages=219–22 |year=1989 |month=March |pmid=2493578 |doi= 10.1016/0165-1218(89)90137-7|url=}}</ref> It is poorly absorbed from the [[gastrointestinal tract]] and is used as a luminal agent to eradicate both [[cyst]]s and [[trophozoite]]s infestating the lumen of the gastrointestinal tract. Iodoquinol is not recommended for prolonged use due to associated toxicities (eg, [[optic neuritis]], [[optic atrophy]], and [[peripheral neuropathy]]). | ||
==Category== | ==Category== | ||
| Line 19: | Line 19: | ||
'''| [[Iodoquinol contraindications|Contraindications]]''' | '''| [[Iodoquinol contraindications|Contraindications]]''' | ||
'''| [[Iodoquinol warnings|Warnings]]''' | '''| [[Iodoquinol warnings|Warnings]]''' | ||
'''| [[Iodoquinol use in pregnancy|Use in Pregnancy]]''' | '''| [[Iodoquinol use in pregnancy|Use in Pregnancy]]''' | ||
'''| [[Iodoquinol precautions|Precautions]]''' | '''| [[Iodoquinol precautions|Precautions]]''' | ||
Latest revision as of 23:59, 30 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The quinoline derivative diiodohydroxyquinoline (INN) or iodoquinol (USAN) can be used in the treatment of amebiasis, balantidiasis, and Dientamoeba fragilis.[1] It is poorly absorbed from the gastrointestinal tract and is used as a luminal agent to eradicate both cysts and trophozoites infestating the lumen of the gastrointestinal tract. Iodoquinol is not recommended for prolonged use due to associated toxicities (eg, optic neuritis, optic atrophy, and peripheral neuropathy).
Category
Amebicide
US Brand Names
YODOXIN®
Package Insert
Description | Inactive Ingredients | Action | Indications | Contraindications | Warnings | Use in Pregnancy | Precautions | Adverse Reactions | Dosage and Administration | How Supplied | Storage
Mechanisms of Action
Iodoquinol acts by chelation of Fe2+ which is essential for metabolism.